E. P. Krenning

16.7k citations

168 papers · 12.7k indexed · 5 hit papers · h-index 58

Impact in

Neurology top 0.1%
- Neuroblastoma Research and Treatments
Oncology top 0.2%
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research

Papers in

Neurology 67
- Neuroblastoma Research and Treatments 63
Epidemiology 107
- Neuroendocrine Tumor Research Advances 100

Co-authors: Dik J. Kwekkeboom Marion de Jong Jean Claude Reubi J.C. Reubi Wout A. P. Breeman P.P.M. Kooij Steven W. J. Lamberts Willem H. Bakker
Journals: European Journal of Nuclear Medicine and Molecular Imaging (17 papers)Annals of Oncology (11 papers)The Journal of Clinical Endocrinology & Metabolism (11 papers)Neuroendocrinology (6 papers)Nuclear Medicine Communications (6 papers)
Partner nations: Netherlands United States Switzerland

In The Last Decade

E. P. Krenning

167 papers receiving 12.3k citations

Hit Papers

5 papers align trajectories log scale

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2020 · 653 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Annals of Oncology
2016 Neuroendocrinology
2016 Neuroendocrinology
1993 European Journal of Nuclear Medicine and Molecular Imaging
1989 The Lancet

Peers

Countries citing papers authored by E. P. Krenning

Since Specialization

Citations

This map shows the geographic impact of E. P. Krenning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. P. Krenning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. P. Krenning more than expected).

Fields of papers citing papers by E. P. Krenning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. P. Krenning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. P. Krenning. The network helps show where E. P. Krenning may publish in the future.

Co-authors

The 25 scholars most cited alongside E. P. Krenning, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. P. Krenning Line = papers co-authored together E. P. Krenning links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology ·Marianne Pavel, Kjell Öberg, M. Falconi, E. P. Krenning, Anders Sundin, Aurel Perren, Alfredo Berruti Hit paper breakdown →	2020	653
2	A randomized controlled study comparing treatment of gastro-entero-pancreatic neuroendocrine tumors (GEPNET) with 177Lu-DOTATATE alone and in combination with capecitabine Neuroendocrinology ·W. Van der Zwan, David Wyld, Tessa Brabander, Jaap J.M. Teunissen, Boen L.R. Kam, David G. Macfarlane, E. P. Krenning, Dik J. Kwekkeboom, WW de Herder	2018	3
3	Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging ·Wouter A. van der Zwan, Tessa Brabander, Boen L.R. Kam, Jaap J.M. Teunissen, Richard A. Feelders, Johannes Hofland, E. P. Krenning, Wouter W. de Herder	2018	99
4	NETTER-1 Phase III Trial : Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors Neuroendocrinology ·J. Strosberg, Edward M. Wolin, Beth Chasen, M. Kulke, David Bushnell, M. Caplin, R. P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Lopera M. Sierra, D. J. Kwekkeboom, P. Ruszniewski, E. P. Krenning	2017	2
5	NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis Annals of Oncology ·Jonathan Strosberg, Edward M. Wolin, B. Chasen, Matthew H. Kulke, D. Bushnell, Martyn Caplin, R. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, K. Öberg, Maribel Lopera Sierra, D. J. Kwekkeboom, P. Ruszniewski, E. P. Krenning	2016	2
6	Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues Methods ·Rogier P. J. Schroeder, Wytske M. van Weerden, Chris Bangma, E. P. Krenning, Marion de Jong	2009	67
7	Estrogen Receptor α Gene Polymorphisms and Bone Mineral Density in Healthy Children and Young Adults Calcified Tissue International ·Annemieke M. Boot, Inge M. van der Sluis, Sabine M.P.F. de Muinck Keizer‐Schrama, Joyce B. J. van Meurs, E. P. Krenning, Huibert A. P. Pols, André G. Uitterlinden	2004	46
8	Phase 1 study of peptide receptor radionuclide therapy (PRRT) with [Y-90-DOTA,Tyr(3)]octreotide in patients with somatostatin receptor positive tumors Cancer Biotherapy and Radiopharmaceuticals ·Roelf Valkema, François Jamar, Stanislas Pauwels, Larry K. Kvols, Raffaella Barone, WH Bakker, Janet Lasher, E. P. Krenning	2003	7
9	Somatostatin receptor scintigraphy useful in stage I–II Hodgkin's disease: more extended disease identified British Journal of Haematology ·Pieternella J. Lugtenburg, E. P. Krenning, Roelf Valkema, H.Y. Oei, Steven W. J. Lamberts, M. J. C. Eijkemans, Wim L.J. van Putten, Bob Löwenberg	2001	31
10	Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer Journal of Endocrinological Investigation ·L. M. Haslinghuis, E. P. Krenning, Wouter W. de Herder, Ambroos E.M. Reijs, Dik J. Kwekkeboom	2001	37
11	Receptor imaging in the diagnosis and treatment of pituitary tumors (multiple letters) [1] Journal of Endocrinological Investigation ·Annamaria Colao, Secondo Lastoria, Gaetano Lombardi, Dik J. Kwekkeboom, Wouter W. de Herder, E. P. Krenning	1999	1
12	Bone mineral density and nutritional status in children with chronic inflammatory bowel disease Gut ·Annemieke M. Boot, J. Bouquet, E. P. Krenning, Sabine M.P.F. de Muinck Keizer‐Schrama	1998	168
13	Internalization of radiolabelled [DTPA0]octreotide and [DOTA0, Tyr3]octreotide Nuclear Medicine Communications ·Marion de Jong, Bert F. Bernard, Elza de Bruin, Arthur van Gameren, Willem H. Bakker, T.J. Visser, Helmut R. Mäcke, E. P. Krenning	1998	99
14	Cost-effectiveness analysis of somatostatin receptor scintigraphy. PubMed ·D. J. Kwekkeboom, Steven W. J. Lamberts, J D Habbema, E. P. Krenning	1996	38
15	The relevance of somatostatin receptor expression in malignant lymphomas Metabolism ·P.J. van den Anker-Lugtenburg, Bob Löwenberg, Steven W. J. Lamberts, E. P. Krenning	1996	16
16	The value of octreotide scintigraphy in patients with lung cancer European Journal of Nuclear Medicine and Molecular Imaging ·DikJ. Kwekkeboom, G.S. Kho, StevenW.J. Lamberts, Jean–Claude Reubi, JeanA. Laissue, E. P. Krenning	1994	86
17	Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients European Journal of Nuclear Medicine and Molecular Imaging ·E. P. Krenning, Dik J. Kwekkeboom, Willem H. Bakker, Wout A. P. Breeman, P.P.M. Kooij, H.Y. Oei, M. van Hagen, P.T.E. Postema, Marion de Jong, Jean Claude Reubi, T. J. Visser, Ambroos E.M. Reijs, Leo J. Hofland, Jan W. Koper, S. W. J. Lamberts Hit paper breakdown →	1993	1193
18	In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats Life Sciences ·Willem H. Bakker, E. P. Krenning, J.C. Reubi, Wout A. P. Breeman, Buddy Setyono-Han, Marion de Jong, P.P.M. Kooij, Christian Bruns, P. Martin van Hagen, Peter Marbach, T.J. Visser, Jeanetta du Plessis, S. W. J. Lamberts	1991	141
19	LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN The Lancet ·E. P. Krenning, Wout A. P. Breeman, P.P.M. Kooij, Laméris Js, W.H. Bakker, J. W. Koper, L Ausema, Jean Claude Reubi, S.W.J. Lamberts Hit paper breakdown →	1989	481
20	Active Transport of Iodothyronines into Human Cultured Fibroblasts* The Journal of Clinical Endocrinology & Metabolism ·R. Docter, E. P. Krenning, H.F. Bernard, G Hennemann	1987	37

About E. P. Krenning

E. P. Krenning is a scholar working on Neurology, Epidemiology, Endocrinology, Diabetes and Metabolism, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 168 papers that have together received 12.7k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (100 papers), Neuroblastoma Research and Treatments (63 papers), Lung Cancer Research Studies (57 papers), Thyroid Disorders and Treatments (29 papers), Radiopharmaceutical Chemistry and Applications (26 papers), Growth Hormone and Insulin-like Growth Factors (18 papers), Pituitary Gland Disorders and Treatments (17 papers) and Medical Imaging Techniques and Applications (14 papers). The work is most often cited by research in Neurology (5.2k citations), Oncology (6.7k citations), Epidemiology (8.4k citations), Endocrinology, Diabetes and Metabolism (2.5k citations) and Radiology, Nuclear Medicine and Imaging (2.9k citations). E. P. Krenning has collaborated with scholars based in Netherlands, United States and Switzerland. Frequent co-authors include Dik J. Kwekkeboom, Marion de Jong, Jean Claude Reubi, J.C. Reubi, Wout A. P. Breeman, P.P.M. Kooij, Steven W. J. Lamberts, Willem H. Bakker, T. J. Visser and R. Docter. Their work appears in journals such as European Journal of Nuclear Medicine and Molecular Imaging, Annals of Oncology, The Journal of Clinical Endocrinology & Metabolism, Neuroendocrinology and Nuclear Medicine Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact